Revance Therapeutics (RVNC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2017 | 12-2016 | 09-2016 | 06-2016 | 03-2016 | |
| Sales | 75 | 75 | 75 | 75 | 75 |
| Gross Profit | 75 | 75 | 75 | 75 | 75 |
| Operating Expenses | 27,163 | 26,739 | 17,798 | 24,159 | 19,819 |
| Operating Income | -27,088 | -26,664 | -17,723 | -24,084 | -19,744 |
| Interest Expense | 193 | 225 | 256 | 286 | 315 |
| Other Income | 125 | 87 | 1 | -232 | 171 |
| Pre-tax Income | -27,156 | -26,802 | -17,978 | -24,602 | -19,888 |
| Net Income Continuous | -27,156 | -26,802 | -17,978 | -24,602 | -19,888 |
| Net Income | $-27,156 | $-26,802 | $-17,978 | $-24,602 | $-19,888 |
| EPS Basic Total Ops | -0.94 | -0.95 | -0.64 | -0.88 | -0.71 |
| EPS Basic Continuous Ops | -0.94 | -0.95 | -0.64 | -0.88 | -0.71 |
| EPS Diluted Total Ops | -0.94 | -0.95 | -0.64 | -0.88 | -0.71 |
| EPS Diluted Continuous Ops | -0.94 | -0.95 | -0.64 | -0.88 | -0.71 |
| EBITDA(a) | $-26,537 | $-26,104 | $-17,111 | $-23,399 | $-18,944 |